Items Tagged ‘Glioblastoma treatment’

May 30, 2018

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported


Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with […]

View full entry

Tags: Brain Cancer, DCVax, Glioblastoma treatment, immunotherapy, News